A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 17 Apr 2025 Status changed from active, no longer recruiting to completed.
- 03 Feb 2023 Planned End Date changed from 27 Nov 2023 to 31 Mar 2025.
- 03 Feb 2023 Planned primary completion date changed from 27 Nov 2023 to 31 Mar 2025.